Phathom (PHAT) Q1 2026 Earnings Transcript

Phathom Pharmaceuticals reported Q1 2026 net revenue of $58.3 million, up 104% year over year and 1% sequentially, with approximately 268,000 VOQUEZNA prescriptions filled and gross margin holding around 80%. Management reaffirmed full-year 2026 guidance for $320 million to $345 million of revenue and $235 million to $255 million of cash operating expenses, while noting operating profitability is expected by Q3 and positive cash flow in 2027. Commercial momentum remains strong, with covered prescriptions up 91% year over year and NBRx share at 45% among top GI writers, though investors are watching potential competition from a second P-CAB entrant.

Analysis

PHAT is transitioning from a launch story to a category-creation story, and that matters because the second-order value driver is no longer just TRx growth but durability of prescribing behavior. The key signal is not the revenue print itself; it is the widening gap between new-to-brand share and total share in the highest-value prescribers, which implies latent re-acceleration once refills stack on top of new starts. That makes the next two quarters more important than the reported quarter: if covered script momentum holds through the summer while the expanded field force matures, the company can likely bend the market from “interesting specialty launch” to “habit-forming standard of care.”

The biggest hidden beneficiary is actually the existing commercial infrastructure: every incremental physician converted now increases the productivity of the current sales organization without needing proportional headcount growth. That creates operating leverage ahead of the stated profitability inflection, and it also raises the strategic value of the installed base if management later adds adjacent GI assets. On the other side, the imminent second P-CAB entrant is more likely to expand the category than destroy PHAT’s economics; the risk is not share loss from inferiority, but payer behavior if two branded options force tighter utilization management and compress gross-to-net over time.

The main tail risk is timing mismatch: spending rises now while the true primary-care and refill monetization is a 2027+ story. If the company misses the next two quarters of prescription acceleration, the market will re-rate the stock as a cash-burn launch with a good product rather than a platform. The contrarian view is that consensus may be underestimating how much of PHAT’s growth is already self-reinforcing via physician feedback and patient advocacy, which can make the commercial trajectory less linear and less dependent on incremental promotion than bears assume.

Key Decisions for Investors

• Long PHAT for a 3-6 month trading horizon on a momentum continuation setup; use post-earnings consolidation as entry if covered script trends remain positive, targeting a re-rating on evidence of Q2 acceleration and NBRx-to-refill conversion.
• Buy PHAT Jan-2027 calls or call spreads to express the 2027 cash-flow inflection with limited downside; the core risk is payer pressure or a slower-than-expected primary-care ramp, but the payoff improves materially if operating profitability is achieved by Q3 as guided.
• Pair trade: long PHAT / short a basket of mature GI or promo-light pharma names on the view that PHAT’s incremental commercial leverage is being underestimated relative to slower-growth peers; size modestly because category entry risk remains real.
• Hedge against competitive-risk headlines by buying short-dated PHAT puts into the next P-CAB data/launch window if the stock rallies sharply; the tape is likely to overreact to competitor superiority claims even if real-world substitution risk is low.